Elicio Therapeutics (ELTX) Total Liabilities (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Total Liabilities data on file, last reported at $24.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 25.4% year-over-year to $24.1 million; the trailing twelve-month figure through Mar 2026 stood at $24.1 million (up 25.4% YoY), and the FY2025 full-year result was $24.2 million, down 38.65% from the prior year.
• Total Liabilities for Q1 2026 stood at $24.1 million, roughly flat from $24.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $57.4 million in Q3 2024 and bottomed at $2.1 million in Q1 2023.
• The 5-year median for Total Liabilities is $17.7 million (2023), against an average of $20.8 million.
• The widest annual swing landed in 2023, when Total Liabilities sank 85.05%; it then soared 833.37% in 2024.
• A 5-year view of Total Liabilities shows it stood at $13.7 million in 2022, then grew by 14.72% to $15.8 million in 2023, then surged by 150.36% to $39.5 million in 2024, then sank by 38.65% to $24.2 million in 2025, then slipped by 0.41% to $24.1 million in 2026.
• The last three Total Liabilities figures came in at $24.1 million (Q1 2026), $24.2 million (Q4 2025), and $24.5 million (Q3 2025), per Business Quant data.

Peer Comparison